Síndrome metabólico y diabetes mellitus

González Sarmiento, Enrique; Pascual Calleja, Isaac; Laclaustra Gimeno, Martín; Casasnovas Lenguas, José A.

doi:10.1016/S1131-3587(05)74118-2

Información del artículo

Resumen

Bibliografía

Descargar PDF

Estadísticas

La diabetes mellitus (DM) es una enfermedad metabólica crónica que está adquiriendo en los últimos años proporciones de auténtica epidemia. Se asocia frecuentemente con obesidad, alteraciones del metabolismo lipídico y proteínico, así como con hipertensión arterial y otros factores de riesgo cardiovascular, lo que constituye el síndrome metabólico. La DM tipo 2 (DM2) es un factor de riesgo importante para la enfermedad coronaria y la aterosclerosis precoz. Su etiopatogenia es multifactorial y está muy relacionada con la resistencia insulínica (RI), que es el proceso fisiopatológico común al conjunto de factores de riesgo cardiovascular. Respecto a la prevención y el tratamiento de la DM2, es fundamental la modificación del estilo de vida, con especial hincapié en la alimentación equilibrada y la introducción del ejercicio físico aeróbico en la vida cotidiana. Cuando las pautas higiénico- dietéticas no son suficientes, se debe recurrir a fármacos que actúen sobre la diana de la resistencia insulínica, como la metformina y las tiazolidinas.

Palabras clave:

Diabetes mellitus tipo 2

Síndrome metabólico

Riesgo cardiovascular

Diabetes mellitus is a chronic metabolic disease that has acquired the nature of an epidemic in recent years. It is frequently associated with obesity, abnormalities of the lipid and protein metabolism, high blood pressure, and other cardiovascular risk factors, which are often clustered together in the metabolic syndrome. Type 2 diabetes mellitus is an important risk factor for coronary disease and premature atherosclerosis. It has a multifactorial pathogenesis and it is closely linked to insulin resistance, which is also involved in the pathophysiology of cardiovascular risk factors associated with metabolic syndrome. One fundamental intervention for the prevention and treatment of type 2 diabetes mellitus is lifestyle modification, in particular the adoption of a balanced diet and the inclusion of aerobic physical activity in daily life. When these measures are insufficient, the use of drugs that target insulin resistance, such as metformin and thiazolidinediones, is necessary.

Key words:

Type 2 diabetes mellitus

Metabolic syndrome

Cardiovascular risk

El Texto completo está disponible en PDF

Bibliografía

[1.]

P. Zimmet, K.G. Alberti, J. Shaw.

Global and societal implications of the diabetes epidemic.

Nature, 414 (2001), pp. 782-787

http://dx.doi.org/10.1038/414782a | Medline

[2.]

American Diabetes Association.

Standars of Medical Care in Diabetes.

Diabetes Care, 28 (2005), pp. S4-S36

Medline

[3.]

A. Goday, M. Serrano-Ríos.

Epidemiología de la diabetes mellitus en España. Revisión crítica y nuevas perspectivas.

Med Clin (Barc), 102 (1994), pp. 306-315

[4.]

D. Molnár.

The prevalence of the metabolic syndrome and type 2 diabetes mellitus in children and adolescents.

Int J Obesity, 28 (2004), pp. S70-S74

[5.]

Expert Panel on Detection, Evaluation, And treatment of High Blood Cholesterol in Adults: executive summary of the Third Report of the National Cholesterol Education program (NECP) Expert Panel on Detection, evaluation, and Treatment of High Blood Choloesterol in Adults (Adult Treatment Panel III).

JAMA, 285 (2001), pp. 2486-2497

Medline

[6.]

The European Group for the study of Insulin Resistance.

The frequency of the WHO Metabolic Syndrome in Europen Cohorts, and an alternative definition of an insulin Resistance Syndrome.

Diabet Med, 28 (2002), pp. 364-376

[7.]

M.P. Stern, K. Willians, C. González-Villalpando, K.J. Hunt, S.M. Haffner.

Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?.

Diabetes Care, 11 (2004), pp. 2676-2681

[8.]

C. Lorenzo, M. Okoloise, K. Willians, M. Stern, S. Haffner.

The metabolic syndrome an predictor of type 2 diabetes. The San Antonio Heart Study.

Diabetes Care, 26 (2003), pp. 3153-3159

Medline

[9.]

E. Bonora, G. Targher, G. Formentini, F. Calcaterra, S. Lombardi, F. Marini, et al.

The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.

Diabetic Med, 21 (2003), pp. 52-58

Medline

[10.]

J.A. Gimeno Orna, L.M. Lou Arnal, E. Molinero Herguedas, B. Boned Julian, D.P. Portilla Córdoba.

Influencia del syndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2.

Rev Esp Cardiol, 57 (2004), pp. 507-513

Medline

[11.]

American Diabetes Association. The prevention or delay of type 2 diabetes. (position statement) Diabetes Care. 2002;25:742-9. (US Prevention Services Task Force: Screening for type 2 diabetes mellitus in adults: recomendations and rationale. Ann Intern Med. 2003;138:212-4.)

[12.]

H.M. Lakka, T.A. Laaksonen, L.K. Niskanen, E. Kumposalo, J. Tuomilehto, J.T. Salonen.

The metabolic syndrome and total and cardiovascular disease mortality in middle-age men.

JAMA, 288 (2002), pp. 2709-2716

Medline

[13.]

H.N. Ginsberg.

Insulin resistance and cardiovascular disease.

J Clin Invest, 106 (2000), pp. 453-458

http://dx.doi.org/10.1172/JCI10762 | Medline

[14.]

M.J. Martinez Calatrava, M.T. Martinez Larrad, M. Serrano Ríos.

Síndrome de resistencia insulínica y síndrome metabólico: similitudes y diferencias. Síndrome metabólico: concepto, fisiopatología y epidemiología.

Cardiovascular RBK Factores, 12 (2003), pp. 89-95

[15.]

F.S. Facchini, A. Riccardo, A. Stoohs, G.M. Reaven.

Enhanced sympathetic nervous system activity: the linchpin between insulin resistance, hyperinsulinemia and heart rare.

Am J Hypertens, 9 (1996), pp. 1013-1017

http://dx.doi.org/10.1016/0895-7061(96)87747-8 | Medline

[16.]

M. Stumvoll, B.J. Goldstein, T.W. Haeften.

Type 2 diabetes: principles of pathogenesis and therapy.

Lancet, 365 (2005), pp. 1333-1346

http://dx.doi.org/10.1016/S0140-6736(05)61032-X | Medline

[17.]

J.R. Zierath, A. Krook, H. Wallberg-Henriksson.

Insulin action and insulin resistance in human skeletal muscle.

Diabetologia, 43 (2000), pp. 821-835

http://dx.doi.org/10.1007/s001250051457 | Medline

[18.]

M. Axelseri, U. Smith, J.W. Erifsson, M.R. Taskinen, P.A. Jansson.

Posprandial hypertriglyceridemia and insulin resístanse in normoglycemic first-degree relatives of patients with type 2 diabetes.

Ann Intern Med, 131 (1999), pp. 27-31

Medline

[19.]

S.E. Kahn.

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus.

Am J Med, 108 (2000), pp. S2-S8

[20.]

C. Weyer, C. Bogardus, D.M. Mott, R.E. Pratley.

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

J Clin Invest, 104 (1999), pp. 787-794

http://dx.doi.org/10.1172/JCI7231 | Medline

[21.]

Diabetes Prevention Program Research Group.

Reduction in incidence of type 2 diabetes with lifestyle intervention or Metformin.

N Engl J Med, 346 (2002), pp. 393-403

http://dx.doi.org/10.1056/NEJMoa012512 | Medline

[22.]

J. Tuamiletho, J. Undstrom, J.G. Ericsson, T.T. Valle, H. Hamalainen, P. Lanne-Parikka.

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjets with impired glucosa tolerance.

N Engl J Med, 344 (2001), pp. 1343-1350

http://dx.doi.org/10.1056/NEJM200105033441801 | Medline

[23.]

J.L. Chiason, R. Gomis, M. Hanefeld, R.G. Josse, A. Karasik, M. Laakso.

The Stop-NIDDM Trial: an internacional study on the efficacy o fan alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucosa tolerance. Rationale, design and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.

Diabetes Care, 346 (1998), pp. 393-403

[24.]

UK Prospective Diabetes Study (UKPDS) Group.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).

Lancet, 352 (1998), pp. 854-865

Medline

[25.]

T.A. Buchanan, A.H. Xiang, R.K. Peters.

Protection from type 2 diabetes persists in the TRIPOD cohort eight months alter stopping troglitazone.

Diabetes, 50 (2001), pp. A81

[26.]

Heart OutcomesPrevention Evaluation (HOPE) Study Investigators.

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of de HOPE study and MICRO-HOPE substudy.

Lancet, 355 (2000), pp. 253-259

Medline

[27.]

American Diabetes Association.

Phisical activity/exercise and diabetes mellitus (position statement).

Diabetes Care, 26 (2003), pp. S73-S77

Medline

[28.]

Consenso del Grupo de Trabajo: Resistencia a la Insulina de la Sociedad Española de Diabetes.

La resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes mellitus tipo 2.

Med Clin (Barc), 119 (2002), pp. 458-463

[29.]

J. Steppel, E. Horton.

Exercise in patients with type 2 diabetes.

Diabetes mellitus: a fundamental and clinical text, pp. 1099-1105

[30.]

American Diabetes Association.

Nutrition principles and recommendations in diabetes (Position Statement), 27 (2004), pp. S36-S46

Medline

[31.]

R.S. Rosenson, C.A. Reasner.

Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.

Curr Opin Cardiol, 19 (2004), pp. 480-487

Medline

[32.]

E. Berger, D.E. Moller.

The mechanisms of action of PPARs.

Annu Rev Med, 53 (2002), pp. 409-435

http://dx.doi.org/10.1146/annurev.med.53.082901.104018 | Medline

[33.]

H. Yki-Järvinen.

Thiazolidinediones.

N Engl J Med, 351 (2004), pp. 1106-1118

http://dx.doi.org/10.1056/NEJMra041001 | Medline

[34.]

Y. Miyazaki, L. Glass, C. Triplitt, M. Matsuda, K. Cusi, A. Mahankali, et al.

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients.

Diabetologia, 44 (2001), pp. 2210-2219

http://dx.doi.org/10.1007/s001250100031 | Medline

[35.]

Y. Miyazaki, A. Mahankali, M. Matsuda.

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

J Clin Endocrinol Metab, 87 (2002), pp. 2784-2791

http://dx.doi.org/10.1210/jcem.87.6.8567 | Medline

[36.]

F. Picard, J. Auwerx.

PPAR(gamma) and glucose homeostasis.

Annu Rev Nutr, 22 (2002), pp. 167-197

http://dx.doi.org/10.1146/annurev.nutr.22.010402.102808 | Medline

[37.]

R.W. Nesto, D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, E.S. Horton, et al.

Thiazolindinedione. Use, fluid retention, and congestive heart failure. A consensus statement from the American Herat Association and American Diabetes Association.

Circulation, 108 (2003), pp. 2941-2948

http://dx.doi.org/10.1161/01.CIR.0000103683.99399.7E | Medline

[38.]

B. Kimmel, S.E. Inzucchi.

Oral agents for type 2 diabetes: an update.

Clin Diab, 23 (2005), pp. 64-76

[39.]

H.E. Lebovitz.

Oral therapie for diabetic hyperglycemia.

Endocrinol Metab Clin N Am, 30 (2001), pp. 909-933

[40.]

H.E. Lebovitz.